Pharvaris Reports the P-III (CHAPTER-3) Trial Data on Deucrictibant XR for Hereditary Angioedema (HAE)

Shots: Pharvaris has reported the P-III (CHAPTER-3) trial (N=85) assessing deucrictibant XR tablet (40mg, QD, PO; n=55) vs PBO (n=30) for the prevention of attacks in adolescents & adults with HAE Trial met all 1 & 2EPs, reducing monthly mean HAE attack rates by 83% overall & 87% in Type 1 or 2 HAE (n=80), with protection beginning within the first Wk. & sustained through 24wks. 1EP results were consistent across subgroups, with trial also showing robust reductions in attack rates & a higher proportion of attack-free pts CHAPTER-3 data will support MAAs planned from H1’27; topline P-III (CREAATE) Part 1 data for the prevention of AAE-C1INH attacks is expected in Q1’27, with a US NDA filing planned for the prophylaxis of bradykinin-mediated angioedema attacksin H1’27 Ref: Globenewswire | Image: Pharvaris  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Pharvaris Reports the P-III (CHAPTER-3) Trial Data on Deucrictibant XR for Hereditary Angioedema (HAE) appeared first on PharmaShots.